The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Open accessAbstract
Objective: The Parkinson's Progression Markers Initiative (PPMI) is an observational, international study designed to establish biomarker‐defined cohorts and identify clinical, imaging, genetic, and biospecimen Parkinson's disease (PD) progression markers to accelerate disease‐modifying therapeutic trials. Methods: A total of 423 untreated PD, 196 Healthy Control (HC) and 64 SWEDD (scans without evidence of dopaminergic deficit) subjects were enrolled at 24 sites. To enroll PD subjects as early as possible following diagnosis, subjects were eligible with only asymmetric bradykinesia or tremor plus a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition of data was standardized as detailed at www.ppmi-info.org. Results: Approximately 9% of enrolled subjects had a single PD sign at baseline. DAT imaging excluded 16% of potential PD subjects with SWEDD. The total MDS‐UPDRS for PD was 32.4 compared to 4.6 for HC and 28.2 for SWEDD. On average, PD subjects demonstrated 45% and 68% reduction in mean striatal and contralateral putamen Specific Binding Ratios (SBR), respectively. Cerebrospinal fluid (CSF) was acquired from >97% of all subjects. CSF (PD/HC/SWEDD pg/mL) α‐synuclein (1845/2204/2141) was reduced in PD vs HC or SWEDD (P < 0.03). Similarly, t‐tau (45/53) and p‐tau (16/18) were reduced in PD versus HC (P < 0.01), Interpretation: PPMI has detailed the biomarker signature for an early PD cohort defined by clinical features and imaging biomarkers. This strategy provides the framework to establish biomarker cohorts and to define longitudinal progression biomarkers to support future PD treatment trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Adams, J. L., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W., Goldenthal, S., Biglan, K. M., et al. (2017) · Digital Biomarkers · doi:10.1159/000479018 · Cited by 3,171
Wechsler Adult Intelligence Scale
(2007) · Encyclopedia of Measurement and Statistics · doi:10.4135/9781412952644.n478 · Cited by 2,008
The Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Self-citationLevodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument
Stiasny‐Kolster, K., Mayer, G., Schäfer, S., Möller, J. C., Heinzel‐Gutenbrunner, M., & Oertel, W. H. (2007) · Movement Disorders · doi:10.1002/mds.21740 · Cited by 1,060
Visuospatial Judgment: A Clinical Test
Benton, A. L. (1978) · Archives of Neurology · doi:10.1001/archneur.1978.00500300038006 · Cited by 1,012
The MoCA: Well-suited screen for cognitive impairment in Parkinson disease
Dalrymple-Alford, J. C., MacAskill, M. R., Nakas, C. T., Livingston, L., Graham, C., Crucian, G. P., Melzer, T. R., Kirwan, J., Keenan, R., Wells, S., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fc29c9 · Cited by 932
Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT
Visser, M., Marinus, J., Stiggelbout, A. M., & Van Hilten, J. J. (2004) · Movement Disorders · doi:10.1002/mds.20153 · Cited by 831
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Benamer, H. T. S., Patterson, J., Grosset, D. G., Booij, J., de Bruin, K., van Royen, E., Speelman, J. D., Horstink, M. H. I. M., Sips, H. J. W. A., Dierckx, R. A., et al. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<503::aid-mds1013>3.0.co;2-v · Cited by 707
Knight, R. G., Waal‐Manning, H. J., & Spears, G. F. (1983) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1983.tb00610.x · Cited by 693
The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study
Foltynie, T., Brayne, C. E. G., Robbins, T. W., & Barker, R. A. (2004) · Brain · doi:10.1093/brain/awh067 · Cited by 688
Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 622
Self-citationDJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Self-citationIdentifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
Postuma, R. B., Aarsland, D., Barone, P., Burn, D. J., Hawkes, C. H., Oertel, W., & Ziemssen, T. (2012) · Movement Disorders · doi:10.1002/mds.24996 · Cited by 612
Norms for Letter and Category Fluency: Demographic Corrections for Age, Education, and Ethnicity
Gladsjo, J. A., Schuman, C. C., Evans, J. D., Peavy, G. M., Miller, S. W., & Heaton, R. K. (1999) · Assessment · doi:10.1177/107319119900600204 · Cited by 548
Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease
Weintraub, D., Hoops, S., Shea, J. A., Lyons, K. E., Pahwa, R., Driver‐Dunckley, E. D., Adler, C. H., Potenza, M. N., Miyasaki, J., Siderowf, A. D., et al. (2009) · Movement Disorders · doi:10.1002/mds.22571 · Cited by 528
Self-citationGenetic insights into common pathways and complex relationships among immune-mediated diseases
Parkes, M., Cortes, A., van Heel, D. A., & Brown, M. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3502 · Cited by 526
Thenganatt, M. A., & Jankovic, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6233 · Cited by 506
Berg, D., Postuma, R. B., Bloem, B., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Hardy, J., Lang, A. E., et al. (2014) · Movement Disorders · doi:10.1002/mds.25844 · Cited by 506
Self-citationNeuropathology underlying clinical variability in patients with synucleinopathies
Halliday, G. M., Holton, J. L., Revesz, T., & Dickson, D. W. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0852-9 · Cited by 430
Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study
Yarnall, A. J., Breen, D. P., Duncan, G. W., Khoo, T. K., Coleman, S. Y., Firbank, M. J., Nombela, C., Winder-Rhodes, S., Evans, J. R., Rowe, J. B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000066 · Cited by 422
Self-citationDaytime sleepiness and other sleep disorders in Parkinson’s disease
Ondo, W. G., Dat Vuong, K., Khan, H., Atassi, F., Kwak, C., & Jankovic, J. (2001) · Neurology · doi:10.1212/wnl.57.8.1392 · Cited by 386
Hopkins Verbal Learning Test--Revised
Benedict, R. H. B., Schretlen, D., Groninger, L., & Brandt, J. (2013) · PsycTESTS Dataset · doi:10.1037/t10851-000 · Cited by 375
Kang, J.-H. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3861 · Cited by 367
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub, D., Simuni, T., Caspell‐Garcia, C., Coffey, C., Lasch, S., Siderowf, A., Aarsland, D., Barone, P., Burn, D., Chahine, L. M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26170 · Cited by 305
Self-citationThe spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease
Aarsland, D., Bronnick, K., Alves, G., Tysnes, O. B., Pedersen, K. F., Ehrt, U., & Larsen, J. P. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.166959 · Cited by 300
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Initiative, T. A. D. N., Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Figurski, M., Coart, E., Blennow, K., Soares, H., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 298
Self-citationMixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
The Parkinson Study Group PRECEPT Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000277648.63931.c0 · Cited by 292
Catafau, A. M., & Tolosa, E. (2004) · Movement Disorders · doi:10.1002/mds.20112 · Cited by 290
Weintraub, D., Oehlberg, K. A., Katz, I. R., & Stern, M. B. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000192488.66049.4b · Cited by 278
Self-citationCourse in Parkinson disease subtypes: A 39-year clinicopathologic study
Rajput, A. H., Voll, A., Rajput, M. L., Robinson, C. A., & Rajput, A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ae7af1 · Cited by 270
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Varrone, A., Dickson, J. C., Tossici-Bolt, L., Sera, T., Asenbaum, S., Booij, J., Kapucu, O. L., Kluge, A., Knudsen, G. M., Koulibaly, P. M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2276-8 · Cited by 250
Alves, G., Bronnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., Kurz, M. W., Andreasson, U., Tysnes, O.-B., Larsen, J. P., et al. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199950 · Cited by 221
MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE
Wang, L. H., & Johnson, E. M. (2008) · Neurology · doi:10.1212/01.wnl.0000324506.93877.5e · Cited by 204
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
Schapira, A. H., McDermott, M. P., Barone, P., Comella, C. L., Albrecht, S., Hsu, H. H., Massey, D. H., Mizuno, Y., Poewe, W., Rascol, O., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70117-0 · Cited by 203
Self-citationDoty, R. L., Bromley, S. M., & Stern, M. B. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0011 · Cited by 187
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort
Mollenhauer, B., Trautmann, E., Sixel-Döring, F., Wicke, T., Ebentheuer, J., Schaumburg, M., Lang, E., Focke, N. K., Kumar, K. R., Lohmann, K., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a6cbd5 · Cited by 182
Self-citationCSF Aβ42 and tau in Parkinson's disease with cognitive impairment
Montine, T. J., Shi, M., Quinn, J. F., Peskind, E. R., Craft, S., Ginghina, C., Chung, K. A., Kim, H., Galasko, D. R., Jankovic, J., et al. (2010) · Movement Disorders · doi:10.1002/mds.23287 · Cited by 182
Self-citationCerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D'Amore, C., Pierguidi, L., Tambasco, N., Rossi, A., & Calabresi, P. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.016 · Cited by 173
Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study
Jennings, D., Siderowf, A., Stern, M., Seibyl, J., Eberly, S., Oakes, D., Marek, K., & For the PARS Investigators (2014) · Neurology · doi:10.1212/wnl.0000000000000960 · Cited by 171
Self-citationLongitudinal follow-up of SWEDD subjects in the PRECEPT Study
Marek, K., Seibyl, J., Eberly, S., Oakes, D., Shoulson, I., Lang, A. E., Hyson, C., Jennings, D., & For The Parkinson Study Group PRECEPT Investigators (2014) · Neurology · doi:10.1212/wnl.0000000000000424 · Cited by 168
Self-citationTotal CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel‐Döring, F., Ebentheuer, J., Trenkwalder, C., & Schlossmacher, M. G. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.004 · Cited by 144
Self-citationDefining at‐risk populations for Parkinson's disease: Lessons from ongoing studies
Berg, D., MAREK, K. L., Ross, G. W., & Poewe, W. H. (2012) · Movement Disorders · doi:10.1002/mds.24985 · Cited by 130
Self-citationLevodopa and the progression of Parkinson’s disease
Morgan, J. C., & Sethi, K. D. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0069-1 · Cited by 123
Recent developments in biomarkers in Parkinson disease
Schapira, A. H. V. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283633741 · Cited by 112
Nobili, F. M., Campus, C., Arnaldi, D., Carli, F. D., Cabassi, G., Brugnolo, A., Dessi, B., Morbelli, S. D., Sambuceti, G., Abbruzzese, G., et al. (2010) · Movement Disorders · doi:10.1002/mds.22899 · Cited by 99
Goetz, C. G., Stebbins, G. T., Chmura, T. A., Fahn, S., Poewe, W. H., & Tanner, C. M. (2010) · Movement Disorders · doi:10.1002/mds.23096 · Cited by 78
Self-citationSafety of Lumbar Puncture Procedures in Patients with Alzheimers Disease
Peskind, E., Nordberg, A., Darreh-Shori, T., & Soininen, H. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486509 · Cited by 66
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits
Schuff, N. W., Wu, I., Buckley, S. T., Foster, E. D., Coffey, C. S., Gitelman, D. R., Mendick, S., Seibyl, J. P., Simuni, T., Zhang, Y., et al. (2015) · Movement Disorders · doi:10.1002/mds.26325 · Cited by 58
Self-citationSiderowf, A. D., Pontecorvo, M. J., Shill, H. A., Mintun, M. A., Arora, A., Joshi, A. D., Lu, M., Adler, C. H., Galasko, D. R., Liebsack, C., et al. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-79 · Cited by 47
Self-citationCerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers
Aasly, J. O., Shi, M. Y., Sossi, V., Stewart, T., Johansen, K. K., Wszołek, Z. K., Uitti, R. J., Hasegawa, K., Yokoyama, T., Zabetian, C. P., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823ed101 · Cited by 42
An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2
Zhu, L., Liu, Y., Plöessl, K., Lieberman, B. P., Liu, J., & Kung, H. F. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.10.005 · Cited by 41
Seibyl, J. P., Kupsch, A. R., Booij, J., Grosset, D. G., Costa, D. C., Hauser, R. A., Darcourt, J., Bajaj, N. P. S., Walker, Z., MAREK, K. L., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.140228 · Cited by 22
Self-citation
Cited by
Siderowf, A., Concha-Marambio, L., Lafontant, D.-E., Farris, C. M., Ma, Y., Urenia, P. A., Nguyen, H., Alcalay, R. N., Chahine, L. M., Foroud, T., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00109-6 · Cited by 719
Self-citationSimuni, T., Chahine, L. M., Poston, K., Brumm, M., Buracchio, T., Campbell, M., Chowdhury, S., Coffey, C., Concha-Marambio, L., Dam, T., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00405-2 · Cited by 629
Self-citationBrain-First versus Gut-First Parkinson’s Disease: A Hypothesis
Borghammer, P., & Van Den Berge, N. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191721 · Cited by 419
Helmich, R. C., & Bloem, B. R. (2020) · Journal of Parkinson's Disease · doi:10.3233/jpd-202038 · Cited by 300
Effect of data leakage in brain MRI classification using 2D convolutional neural networks
Yagis, E., Atnafu, S. W., García Seco de Herrera, A., Marzi, C., Scheda, R., Giannelli, M., Tessa, C., Citi, L., & Diciotti, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-01681-w · Cited by 161
Metadata
- Authors
- Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., Coffey, C. S., Caspell‐Garcia, C., Simuni, T., Jennings, D., Tanner, C. M., Trojanowski, J. Q., Shaw, L. M., Seibyl, J., Schuff, N., Singleton, A., Kieburtz, K., Toga, A. W., Mollenhauer, B., Galasko, D., Chahine, L. M., Weintraub, D., Foroud, T., Tosun‐Turgut, D., Poston, K., Arnedo, V., Frasier, M., Sherer, T., & Initiative, T. P. P. M.
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2018-10-31
- Volume
- 5
- Issue
- 12
- Pages
- 1460-1477
- ISSN
- 2328-9503 (ISSN-L)
- OpenAlex
- W2898850833
- Cited by
- 671
- References
- 58
- FWCI
- 17.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.